Diego M. Cecchini

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

Published: June 16, 2026

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

Journal: AIDS (London, England)

Published: March 14, 2026

Guidance on the clinical management of HIV-1 persistent low-level viraemia on antiretroviral treatment: a scoping review and an international Delphi consensus.

Guidance on the clinical management of HIV-1 persistent low-level viraemia on antiretroviral treatment: a scoping review and an international Delphi consensus.

Journal: The lancet. HIV

Published: February 10, 2026

Chemsex Practice Among PrEP Users in Buenos Aires, Argentina.

Chemsex Practice Among PrEP Users in Buenos Aires, Argentina.

Journal: AIDS and behavior

Published: January 08, 2026

Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease.

Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease.

Journal: Medicina

Published: October 18, 2025

Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice.

Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice.

Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

Published: June 16, 2025

Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.

Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 28, 2025

Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires, Argentina.

Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires, Argentina.

Journal: Viruses

Published: April 07, 2025

Baseline survey of doravirine resistance among pregnant women with HIV.

Baseline survey of doravirine resistance among pregnant women with HIV.

Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

Published: February 10, 2025

Antiretroviral Therapy Adherence and Clinic Attendance Over Time Among People in Argentina Living with HIV and Lost to Care.

Antiretroviral Therapy Adherence and Clinic Attendance Over Time Among People in Argentina Living with HIV and Lost to Care.

Journal: International journal of behavioral medicine

Published: February 09, 2025

Clinical and epidemiological characteristics of the 2022-2023 Mpox outbreak in Buenos Aires, Argentina.

Clinical and epidemiological characteristics of the 2022-2023 Mpox outbreak in Buenos Aires, Argentina.

Journal: Medicina

Published: February 03, 2025

Global "expiration" of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART.

Global "expiration" of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART.

Journal: Therapeutic advances in infectious disease

Published: January 25, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026